PD-1 Horse Race: Do Keytruda's Latest Lung Data Give Opdivo An Edge?
This article was originally published in The Pink Sheet Daily
Executive Summary
Some analysts see overall survival data for Merck's Keytruda in the KEYNOTE-010 lung cancer study as weaker than Bristol’s Opdivo in other trials, but different patient populations could explain the variations.